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There remains an unmet need for effective therapies for front-line treatment of Malignant 
Pleural Mesothelioma (MPM). Heatshock protein 90 (Hsp90) inhibition reportedly induce 
apoptosis in MPM and mediate synergistic cisplatin-related toxicity in pre-clinical studies. 
Ganetespib, a potent small molecule Hsp90 inhibitor, demonstrates significant activity for 
down-regulating Hsp90 client protein levels with acceptable toxicity in single-agent phase II 
solid tumor studies. Furthermore, Hsp90 inhibition with ganetespib can enhance T-cell-
mediated anti-tumor immune response. We present the MESO-02 trial of ganetespib plus 
pemetrexed and cisplatin/carboplatin in chemotherapy-naïve MPM patients. This novel 
combination was well-tolerated. We observed promising anti-tumor activity including partial 
responses, particularly in patients with epithelioid histology, and Loss of Heterozygosity was 
associated with shorter time to progression. Response rates of ganetespib are comparable 
or better than those observed in other novel-agent MPM trials. This study supports further 













Ganetespib, a highly potent, small molecule Heatshock protein 90 inhibitor, has potential 
efficacy in malignant pleural mesothelioma (MPM) via activity on critical survival pathways 
and known synergies with antifolates and platinum chemotherapy. We conducted a dose-
escalation study to identify the Maximum Tolerated Dose (MTD) of ganetespib in 
chemotherapy-naïve MPM patients. 
Experimental Design 
MESO-02 (ClinicalTrials.gov: NCT01590160) was a non-randomized, multicentre, phase Ib 
trial of 3-weekly ganetespib (100 mg/m2, 150 mg/m2, 200 mg/m2; days 1 and 15) with 
pemetrexed (500 mg/m2; day 1) and cisplatin (75 mg/m2; day 1) or carboplatin (area under 
concentration-time curve 5; day 1) in MPM patients. Dose-escalation was performed using 
the 3+3 design (cisplatin) and accelerated titration design (carboplatin). Secondary 
endpoints included best response, progression-free survival (PFS) and pharmacogenomic 
analyses.  
Results 
Of 27 patients enroled (cisplatin, n=16; carboplatin, n=11), 3 experienced dose-limiting 
toxicities: grade 3 nausea (cisplatin, n=1; carboplatin, n=1); grade 2 infusion-related reaction 
(carboplatin, n=1). Ganetespib’s MTD was 200 mg/m2. Partial response was observed in 
14/27 patients (52%; 61% in 23 response-evaluable patients) and 13/21 (62%) with 
epithelioid histology. At the MTD, 10/18 patients (56%) had partial response, 15/18 (83%) 
had disease control, and median PFS was 6.3 months (95% CI 5.0-10.0). One responder 
exhibited disease control beyond 50 months. Global Loss of Heterozygosity was associated 




Ganetespib can be combined safely with pemetrexed and platinum chemotherapy to treat 
patients with MPM. This class of agent should be investigated in larger randomized studies.  
 







Malignant pleural mesothelioma (MPM) is an incurable, rapidly lethal cancer arising most 
commonly from the parietal pleural mesothelium, and is associated with exposure to 
asbestos. Although the number of deaths due to MPM has increased globally1 there has 
been no new licenced therapy since 2004. The combination of an anti-folate and platinum 
agent is an effective front-line treatment for MPM. Pemetrexed and cisplatin, the approved 
standard, has a response rate of 41.3%, with a median progression free survival (PFS) of 
5.7 months and median overall survival (OS) of 12.1 months2. Using carboplatin instead of 
cisplatin has comparable activity3, and a platinum combination with another anti-folate 
raltitrexed is also effective4.  
There remains an unmet clinical need for new, effective therapies that can improve 
outcomes in the front-line treatment setting. Addition of the vascular endothelial growth 
factor inhibitor bevacizumab to pemetrexed-cisplatin therapy can improve overall survival 
(18.8 months with bevacizumab vs. 16.1 months without; hazard ratio (HR) = 0.77, 
p=0.0167) and progression-free survival (9.2 months with bevacizumab vs. 7.3 months 
without; HR = 0.61, p<0.0001), but is not licenced5, and is only recommended by National 
Comprehensive Cancer Network guidelines to be used in unresectable patients who are able 
to receive bevacizumab6. No positive randomized controlled studies have shown improved 
survival in either the maintenance7 nor relapsed treatment settings8-10. A recent open label 
phase II trial did however show improvement in progression free survival with switch 
maintenance gemcitabine11. 
Heatshock protein 90 (Hsp90) is a molecular chaperone that mediates post-translational 
stabilisation of critical oncogenic signalling molecules, via a repertoire of client proteins that 
include oncogenic kinases relevant to MPM such as AXL and MET12. Hsp90 inhibition has 
been reported to induce apoptosis in MPM via an MCL1 dependent mechanism13 and 
facilitates the evolution of drug resistance14. Acquisition of aneuploidy has been reported as 
a mechanism of resistance to Hsp90 inhibition15. 
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Thymidylate synthase (TS) is a Hsp90 client, implicated in anti-folate resistance which is 
downregulated following inhibition of Hsp9016. Furthermore, pre-clinical studies show that 
inhibition of Hsp90 mediates synergistic toxicity due to cisplatin17. Ganetespib (ADX-1612), 
an Hsp90 inhibitor, is a synthetic quadricyclic triazolone with a small molecular weight that 
binds to the adenosine triphosphate pocket in the N-terminus of Hsp9017,18. Single agent 
ganetespib demonstrates significant activity for down-regulating Hsp90 client protein levels 
with acceptable toxicity at a recommended dose of 200 mg/m2 from phase II studies18,19. 
Furthermore, inhibition of Hsp90 with ganetespib has been shown to enhance T-cell-
mediated anti-tumor immune response20. We hypothesized that the addition of ganetespib to 
pemetrexed and either cisplatin or carboplatin, can be safely delivered, that there might be a 
synergistic interaction clinically, and that patients harbouring genomic instability (reflected in 
somatic copy number alterations, loss of heterozygosity and homozygous deletions) might 
exhibit resistance to ganetespib. 
 
 
MATERIALS AND METHODS 
MESO-02 (ClinicalTrials.gov identifier: NCT01590160) was a multicentre phase I/II study of 
first line ganetespib with pemetrexed/platinum, in patients with malignant pleural 
mesothelioma. Here, we report the results of the phase Ib stage, in which the primary 
objective was to find a safe dose of ganetespib when combined with standard platinum and 
pemetrexed.  A major secondary objective was to examine clinical efficacy. The trial was 
conducted in accordance with the World Medical Association Declaration of Helsinki and 
approved by the UK Medicines and Healthcare Products Regulatory Agency (clinical trial 
authorization number: 20363/0317/001-0001), the Research Ethics Service Committee East 
Midlands, Derby (REC reference no. 12/EM/0448), and the research and development 
9 
 




Key inclusion criteria included: age 18 years or older; histopathological confirmation of MPM, 
with measurable disease using meso-modified Response Evaluation Criteria in Solid Tumors 
(RECIST) v1.021; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 
to 1; adequate haematological status and organ function; and chemotherapy naïve. Key 
exclusion criteria included: evidence of CNS metastases that require local treatment prior to 
systemic cytotoxic chemotherapy; receipt of extensive radiation therapy (except drain site 
radiotherapy), systemic chemotherapy, or other anti-neoplastic therapy within 4 weeks 
before enrolment; uncontrolled intercurrent illnesses; known serious cardiac illness; and 
history of prior gastrointestinal illness. Detailed eligibility criteria are given in the study 
protocol (see Supplementary Appendix). 
 
Treatment 
Patients were given a one-hour intravenous ganetespib infusion on days 1 and 15 of each 
21-day cycle, at one of three dose levels: 100 mg/m2, 150 mg/m2, or 200 mg/m2. Patients 
also received a 10-minute intravenous pemetrexed infusion of 500 mg/m2 (with vitamin B12 
and folate supplementation) immediately after ganetespib infusion on day 1 only. All patients 
received either cisplatin (75 mg/m2 intravenously over 2 hours), or carboplatin (AUC5 
intravenously over 30 minutes), 30 minutes after the completion of pemetrexed infusion. 
Patients in the trial were initially only allowed cisplatin, and once the safety profile was 
shown to be acceptable carboplatin was allowed subsequently (at the clinician’s discretion 
and influenced by expected patient tolerability). Having either platinum agent was 





Within the MESO-02 study there were separate cohorts for cisplatin or carboplatin, to ensure 
acceptable safety of the combination of ganetespib and platinum therapy specifically in MPM 
patients. 
For patients receiving the ganetespib-pemetrexed-cisplatin triplet (i.e. the ‘cisplatin cohort’), 
dose-escalation of ganetespib was conducted using the 3+3 design with a starting dose of 
100 mg/m2. In each cohort, if no dose-limiting toxicities (DLTs) were observed, recruitment 
proceeded to the next cohort of 3 patients. If there was one DLT, the cohort involved was 
expanded to 6. If there were no further DLTs in the cohort of 6, the next cohort was 
administered ganetespib with chemotherapy at the next highest dose. If 2 or more DLTs 
were observed in three or six patients at a given dose, dose-escalation would discontinue 
and no higher dose considered. The cohort at the estimate of the MTD was then expanded 
to 9 patients overall. The maximum planned sample size for the cisplatin cohort was 27 
patients. 
For patients receiving carboplatin with ganetespib and pemetrexed (i.e. the ‘carboplatin 
cohort’), dose-escalation of ganetespib was conducted using an accelerated titration design 
with a starting dose of 100 mg/m2. At dose levels below 200 mg/m2, one patient would 
receive treatment; if no DLT was observed, the next patient would receive the next highest 
dose; otherwise, a 3+3 design would begin (i.e. the same as for the cisplatin-treated cohort). 
If ganetespib reached the estimate of the MTD, the cohort was expanded to 9 patients 
overall. An accelerated titration design was used here as the carboplatin cohort was 
introduced following a protocol amendment after 9 patients had been treated with cisplatin, 
none of whom experienced any DLTs. An accelerated escalation design towards 200 mg/m2 
ganetespib struck a balance between quickly moving towards a likely safe dose, whilst still 
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allowing for re-introduction of a 3+3 procedure if any DLTs were observed. The maximum 
planned sample size for the carboplatin cohort was 18 patients. 
Patients who completed 6 cycles of chemotherapy without signs of disease progression in 
either cohort could go on to receive ganetespib as maintenance monotherapy, using the 
same dose they had already been given. Ganetespib would be given on days 1 and 15 of 
each 21-day cycle, and continued until toxicity, progression, or patients decided to stop. 
 
Patient assessments 
Collection of archival formalin-fixed paraffin-embedded (FFPE) diagnostic tissue was 
mandatory and undertaken at each patient’s screening visit prior to registration. 
Haematological profiling comprised assessment of the haematocrit, haemoglobin, red cell 
count (RCC), white cell count with differential, and platelets, Biochemical profiling comprised 
sodium, potassium, urea, creatinine, chloride, bicarbonate, bilirubin, alkaline phosphatase 
(ALP), aspartate aminotransferase (AST) or alanine aminotransferase (ALT), lactate 
dehydrogenase (LDH), albumin, total protein, calcium, phosphate, magnesium) and 
urinalysis (pH, protein, blood, ketones, glucose). These were conducted before each 
treatment cycle (full blood count and biochemistry, also before day 15 of cycles 1 and 2; 
urinalysis, also before day 15 of cycle 1). Patients underwent a CT scan of the chest and 
abdomen for disease response assessment within 28 days of registration, after 
chemotherapy cycles 2, 4 and 6, then every 6 weeks for 12 months. Scans were assessed 
according to meso-modified RECIST v1.021.  
 
Outcome measures 
Toxicities were graded using the National Cancer Institute’s Common Terminology Criteria 
for Adverse Events (NCI CTCAE v4.0). A DLT was defined as any of the following adverse 
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events deemed definitely, probably, or possibly related to ganetespib therapy: grade 3 or 4 
non-hematologic events except diarrhoea, nausea and vomiting lasting more than 48 hours 
despite maximum medical therapy; grade 4 thrombocytopenia or neutropenia lasting longer 
than 7 days; febrile neutropenia, any drug-related adverse event leading to an interruption of 
ganetespib for longer than 14 days; or any clinically significant toxicity leading to dose 
reduction for ganetespib. DLT assessment applied to cycles 1 and 2 only for patients in the 
cisplatin cohort, and cycle 1 only for the carboplatin cohort. Dose-escalation decisions and 
DLT reviews were made by members of the Trial Management Group. 
Efficacy outcomes were progression-free survival (PFS), the time from study registration to 
confirmed disease progression or death by any cause and overall survival (OS), death by 
any cause, and best response rate (defined as the percentage of patients with a best overall 
response of complete response (CR) or partial response (PR) as per meso-modified 
RECIST v1.0). For DNA copy number analyses, genomic variables of interest were 
somatic copy number alterations (SNCA; number of somatic changes to chromosome 
structure that lead to gain or loss in copies of sections of DNA), global loss of heterozygosity 
(LOH; the number of somatic cells containing only one copy of an allele), and total 
homozygous deletions (total number of biallelic copy number losses). These were assessed 
in the baseline (diagnostic) tumor sample; 80 ng of DNA were extracted from archival 
diagnostic formalin fixed paraffin embedded (FFPE) tissue blocks with the QIAmp DNA 
Mini Kit (Qiagen) and analysed using the OncoScan FFPE Assay Kit (Thermo Fisher), 
which utilizes molecular inversion probe (MIPs) technology. MIP probes were added to 
the FFPE DNA for annealing performed for 16-18 hours. Gap fill reaction was then 
performed. Uncircularized MIP probes and genomic DNA were digested and circular MIP 
probes were linearized and amplified by PCR. Following a second round of PCR 
amplification amplicons were cleaved into smaller DNA fragments with the HaeIII enzyme 
to improve sample hybridization onto the OncoScan arrays. Samples were allowed to 
hybridize for 16-18 hours. After hybridization arrays were stained and washed and loaded 
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into the GeneChip Scanner22. BioDiscovery Nexus Express for OncoScan software was 
then used to define copy number alterations and loss of heterozygosity. The software 
uses the TuScan algorithm to generate an estimate of tumor ploidy and aberrant cell 
fraction at each copy number change. Samples were analysed retrospectively following 
completion of study enrolment, though blinded to knowledge of both safety and efficacy 
outcomes from the patients themselves. 
 
Statistical Analysis 
The MTD of ganetespib plus pemetrexed and platinum therapy was determined by the dose-
escalation design and expansion phase in each platinum therapy cohort. Kaplan Meier 
methods were used to analyse PFS and OS. For exploratory genomic analyses, time to 
progression and associations with genomic variables (SCNA, LOH and total homozygous 
deletions at baseline) were assessed using separate Cox regressions, with each genomic 
variable included as a covariate and time to progression as an outcome (patients with no 
confirmed progression date were censored at last date known to be alive). Spearman’s 
correlation was used to assess the association between best percentage change in total 
tumor burden (TTB, defined as the sum of six pleural measurements in millimetres 
determined by CT scan as per modified RECIST) from baseline and genomic variables. All 








Between 4th September 2013 and 10th November 2015, 27 chemo-naïve patients with a 
confirmed diagnosis of MPM (25 male, 2 female) were recruited. Patient characteristics are 
shown in Table 1. Median age was 66 years (range 37-76). Non-epithelioid MPM accounted 
for 22% of patients. Twenty-one patients (78%) had an ECOG PS 1. Only two patients were 
deemed to have a good prognostic score based on the EORTC prognostic scoring system24. 
There were 16 patients in the cisplatin cohort, and 11 in the carboplatin cohort. 
 
Treatment delivered, toxicity and dose modifications 
Patients in the cisplatin cohort were administered a median of 4 (range 1-6) treatment cycles 
(ganetespib and chemotherapy). Patients in the carboplatin cohort were administered a 
median of 3 (range 1-5) treatment cycles (see Supplementary Table 1). Five patients in the 
carboplatin cohort (45%) chose to withdraw from the study, with two doing so after 
experiencing adverse events; full reasons for treatment discontinuation/withdrawal from the 
study are provided in Supplementary Table 2. Maintenance ganetespib therapy was 
received by a total of 14 patients with a median of 2 cycles (range 1-60), and 2 patients had 
≥10 cycles.  
Supplementary Table 3 shows the DLTs observed in each ganetespib dose cohort. At the 
200 mg/m2 ganetespib dose level when the cohort was expanded from three to nine 
patients, one patient in the cisplatin cohort had a DLT (grade 3 toxicity comprising nausea 
lasting > 48 hours). In the carboplatin cohort at 200 mg/m2 ganetespib, one patient in the first 
three treated experienced DLT (grade 2 infusion related reaction). An additional three 
patients were recruited to this dose level, and no more DLTs were observed. The cohort was 
expanded to nine patients, with one patient experiencing DLT (grade 3 nausea). Given the 
observed DLTs, 200 mg/m2 was considered to be the MTD. 
Grade 3 and 4 toxicities are summarized in Table 2. There were no grade 4 toxicities at the 
100 mg/m2 ganetespib dose level in either the cisplatin or carboplatin cohorts. At the 150 
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mg/m2 dose in the cisplatin cohort, one patient experienced grade 4 hearing impairment. The 
most common grade 3 and 4 adverse effects were all related to anaemia (6 patients; 22%), 
decreased neutrophil counts (4 patients, 15%), and nausea/vomiting (4 patients, 15%). 
Four patients in the cisplatin cohort had reduced cisplatin (median 56 mg/m2; range 37-56) 
for a median of 1 cycle (range 1-2). No dose reductions in ganetespib were required in the 
cisplatin cohort. In the carboplatin cohort, four patients had reduced carboplatin (median 405 
mg/m2; range 250-480), all for 1 cycle. One patient had their ganetespib dose reduced from 
150 mg/m2 to 112mg/m2 (1 of 2 treatment cycles), and another patient assigned to receive 
200 mg/m2 ganetespib did not receive ganetespib on day 15 of cycles 1 and 2 due to 
haematological toxicities. Dose reductions for pemetrexed occurred in four patients in the 
carboplatin cohort (reduction from 500 mg/m2 to 375 mg/m2) and occurred for a median of 1 
cycle (range 1-2).  
 
Efficacy outcomes 
Median observed follow-up time for all patients was 10.7 months (range 2.3-49.4). Median 
follow-up time was 12.3 months (range 3.6-49.4) in the cisplatin cohort, and was 8 months 
(2.3-20.8) in the carboplatin cohort. Overall, 23 patients were evaluable for response (i.e. 
had at least one evaluable response assessment conducted following treatment). Partial 
response (≥30% reduction in total tumor burden from baseline) was observed in 14 out of 27 
patients (Objective Response Rate (ORR) 52%; 95% CI 32%-71%), with 10 out of 18 
patients (56%; 95% CI 31%-78%) receiving 200 mg/m2 of ganetespib achieving a partial 
response (Figure 1). When only based on patients with evaluable disease the ORR was 61% 
(14/23). Twenty-two out of 27 patients (81%) had disease control (partial response or stable 
disease), and one patient had progressive disease. For the 15 evaluable patients treated at 
the MTD, all (100%) had disease control. Patients with non-epithelioid histology had a lower 
ORR (1/6; 17%) compared to patients with epithelioid histology (13/21; ORR 62%; 95% CI 
16 
 
38%-82%). Five out of 6 patients with non-epithelioid histology received lower ganetespib 
doses (100 mg/m2 or 150 mg/m2). However, all but one of the 6 patients with non-epithelioid 
MPM had disease control, stable disease or better (<20% increase in tumor burden). One 
patient receiving the MTD of ganetespib exhibited a prolonged response, reaching its nadir 
after 12 months, and was sustained for over 40 months.  
Nineteen patients had disease progression, and 21 out of 27 patients died. Sixteen patients 
progressed and died later, and 5 patients died without prior reported progression, the causes 
of which were MPM. All 5 of these patients had withdrawn from the trial due to patient choice 
of treatment delay > 28 days and were followed up only for assessing overall survival. In all 
patients, the median PFS was 5.8 months (95% CI 5.0-8.0) (Supplementary Figure 1), 
though was not significantly different between the different platinum therapies (median PFS 
of 5.8 months in both cohorts; HR for cisplatin vs. carboplatin 0.81 (95% CI 0.34-1.91, 
p=0.63)) (Supplementary Figure 2). As with tumor volume, PFS was shown to improve with 
increasing doses of ganetespib, though not statistically significant (log-rank test for trend, 
p=0.10) (Supplementary Figure 3). In patients who had 200 mg/m2, the median PFS was 6.3 
months (95% CI 5.0-10.0). Median overall survival was 11.5 months (95% CI 8.0-19.5) 
(Supplementary Figure 4), but differed across platinum therapies (cisplatin = 14.4 months, 
95% CI 6.3-28.7; carboplatin = 10.6 months, 95% CI 6.3-19.5) (Supplementary Figure 5). 
Overall survival at the MTD was 16.3 months (95% CI 8.0-21.7) (Supplementary Figure 6). 
 
Somatic copy Number Alterations and clinical outcomes 
Aneuploidy has been shown to be associated with acquired resistance to Hsp90. In cell lines 
selected for resistance to ganetespib, we have previously reported large chromosomal 
alterations13. It was hypothesized that response rate to ganetespib-triplet therapy might 
therefore be higher for patients harbouring MPMs with a lower somatic copy number 
alterations. Genome-wide data was acquired for 11 of 27 patients (3 on 100 mg/m2 
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ganetespib (2 cisplatin, 1 carboplatin), 8 on 200 mg/m2 ganetespib (3 cisplatin, 5 
carboplatin); remaining 16 patients provided non-viable samples); Supplementary Table 4 
shows the distribution of these variables over key baseline characteristics. As exploratory 
analyses, correlations and hazard ratios between genomic variables and the change in total 
tumor burden and time to progression respectively are shown in Table 3, with mean and 
standard errors of each genomic variable by best response category presented in 
Supplementary Table 5. Four patients did not have evaluable responses post-baseline. One 
of 7 response-evaluable patients with genomic data recorded (male, cisplatin cohort, 100 
mg/m2 ganetespib) had non-epithelioid histology and stable disease as best response. All 
other response evaluable patients in this exploratory analysis achieved partial response and 
had epithelioid histology. Total LOH was associated with tumor shrinkage (i.e. higher 
baseline LOH associated with smaller reduction in total tumor burden; Spearman’s 
correlation = -0.703, p=0.078; Supplementary Figure 7) and a 12% increase in the risk of 




In MESO-02, we investigated the safety, tolerability and efficacy of intravenous ganetespib 
combined with standard pemetrexed and platinum therapy in patients with MPM. The MTD 
of ganetespib was found to be 200 mg/m2 in both the cisplatin and carboplatin cohorts. The 
trial successfully passed the phase Ib stage. However, the manufacturer of ganetespib 
decided not to proceed to the randomized phase II study following a strategic review and 
mixed findings from other solid tumor trials of ganetespib.  
Ganetespib was well tolerated. At the MTD found in MESO-02, three patients out of 18 
(17%) experienced a DLT. Overall, five patients (18.5%) withdrew from the study due to 
unacceptable/serious adverse events, all of which were grade 2-3. This phase Ib study was 
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not powered to detect improvements in efficacy measures compared to previous work. 
However, our results were highly encouraging; of fifteen patients evaluable for response at 
the MTD, 10 (67%) had a best response of PR and 5 (33%) had stable disease. Median PFS 
at the MTD was 6.3 months and Median OS at the MTD was 16.7 months. One patient 
(male, 63 years old at registration, epithelioid histology, baseline ECOG PS of 0) treated at 
the MTD received maintenance treatment with no observed progression after 60 cycles. 
Whilst these results were obtained from a small sample of MPM patients compared to other 
studies, they indicate that this ganetespib-pemetrexed-platinum therapy combination may be 
worth investigating in a larger randomized double-blind placebo-controlled trial, with 
histology, performance status, previous lines of therapy and baseline LOH as key 
stratification factors. 
Prior to the setup of MESO-02 most trials used 200 mg/m2 ganetespib as monotherapy, 
given weekly for 3 weeks over a 4-week cycle. The regimen used in our trial was considered 
appropriate given the addition of pemetrexed and platinum agents, and that patients could 
continue to have ganetespib as maintenance. The aim was to ensure the majority of patients 
would complete and tolerate at least one cycle of treatment (24 of 27 patients completed at 
least one full cycle). Whilst our study did not explore the tolerability of higher doses of 
ganetespib when combined with pemetrexed and platinum therapy, higher doses of 
ganetespib may still be tolerable. 
MESO-02 recruited a higher percentage of male patients and patients with performance 
status of at least 1 compared to previous MPM studies5,7-10, which led to 93% of patients in 
our trial with a poor baseline EORTC prognosis score, Despite the relatively high rate of non-
epithelioid MPM in the treated cohort (22%) and the trend towards lower response in this 
histological subtype, there was a significant overall response rate (52%) with 62% of patients 
with epithelioid disease responding to treatment. These response rates are among the 
highest reported for any combination treatment in advanced MPM, though the confidence 
intervals are expectedly wide due to the small number of patients. However, this suggests 
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potential activity over and above that of standard chemotherapy, making Hsp90 inhibition a 
real possibility for treating MPM2. Six patients had non-epithelioid MPM; one patient received 
the MTD of ganetespib (200 mg/m2), and another achieved a PR as best response. The 
poorer response of patients with non-epithelioid MPM may be due to the majority of patients 
(5 out of 6) receiving doses lower than the MTD.  
These data are consistent with preclinical evidence supporting a role for Hsp90 in mediating 
DNA repair including homologous recombination, which may underpin synergy of Hsp90 
inhibitors with platinum drugs25,26. Furthermore, thymidylate synthetase, which has been 
shown to correlate with pemetrexed activity is a putative mediator of anti-folate resistance, 
and is downregulated following by Hsp90 inhibition27-29.   
Acquisition of aneuploidy has been reported to be associated with resistance to Hsp90 
inhibition15. We therefore hypothesized that patients harbouring genomic instability (reflected 
in LOH) might exhibit resistance to ganetespib. In our exploratory analyses, we observed a 
statistically significant effect on time to progression, with shorter time to progression for more 
genomically unstable MPMs. However, the results of this need to be interpreted with caution 
as increasing genomic instability per se may be negatively prognostic, and that we only had 
a relatively small number of cases for these analyses30. Nevertheless, our results indicate 
that patients harbouring MPM with high levels of LOH may fail to benefit from addition of 
ganetespib. LOH was associated with a worse clinical outcome, when considering both total 
tumor burden and time to progression. Our study was underpowered to detect any 
interaction between specific copy number alterations and sensitivity to Hsp90 inhibition.  
Chemo-immunotherapy has transformed the front-line treatment of non-small cell lung 
cancer and is currently being developed in studies such as DREAM (NCT04334759), 
PrE505 (NCT02899195), IND227 (NCT02784171) and BEAT-meso (NCT03762018). Of 
note, the single arm PrE505 phase II study had an overall survival of 21 months, significantly 
greater than expected with the standard of care31 and a phase III trial, PrE0506/DREAM3R, 
is planned.  However, combined immune-checkpoint inhibition (ICI) with ipilimumab and 
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nivolumab was recently announced as being superior to pemetrexed-platinum in the pivotal 
Checkmate 743 phase III trial32. This could herald an imminent change of practice in the first-
line setting, creating new second-line development opportunities for novel, non-ICI or ICI-
chemotherapy combinations. Recent evidence suggests that Hsp90 inhibition, through its 
upregulation of interferon response genes, can enhance ICI therapy and pave the way for 
possible future ICI or chemo-immunotherapy combination studies33. In conclusion, 
ganetespib can be safely administered to patients with MPM at 200 mg/m2 when combined 
with pemetrexed and platinum-based chemotherapy. This novel triplet also shows a potential 
signal of activity, for which further evaluation of ganetespib or other Hsp90 inhibitors should 
be done in a larger randomized trial. 
 
Acknowledgements 
We are especially grateful to all the patients and their clinicians for participating in this study. 
MF is supported by the UCL/UCLH NIHR Biomedical Research Centre and runs early phase 
studies in the NIHR UCLH Clinical Research Facility supported by the UCL ECMC. 
 
Author contributions: 
DAF originated the study concept. DAF and AH initially designed the trial, along with DT, SD 
and MF. Patients were recruited by site principal investigators DAF, SD, MF, and DT. 
Statistical analyses were performed by GMW. Genomic analyses were conducted by AS and 
SB. Study management conducted by YN, JC and LF. All authors were involved in writing 
the paper and approved the final version. 
Ganetespib was made available by Madrigal Pharmaceuticals Inc. (formerly Synta 
Pharmaceuticals Corp.). Aldeyra Therapeutics now owns ganetespib. The MESO-02 trial 
was reviewed, endorsed and funded by Cancer Research UK (A11402). The funder was not 
21 
 
involved in: the collection, analysis, or interpretation of data; the writing of study reports; nor 




1. Odgerel CO, Takahashi K, Sorahan T, et al. Estimation of the global burden of mesothelioma 
deaths from incomplete national mortality data. Occup Environ Med 2017; 74(12): 851-8. 
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in 
combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J 
Clin Oncol 2003; 21(14): 2636-44. 
3. Santoro A, O'Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus 
carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the 
International Expanded Access Program. J Thorac Oncol 2008; 3(7): 756-63. 
4. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with 
or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the 
European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National 
Cancer Institute of Canada. J Clin Oncol 2005; 23(28): 6881-9. 
5. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural 
mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, 
controlled, open-label, phase 3 trial. Lancet 2016; 387(10026): 1405-14. 
6. Ettinger DS WD, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, 
D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komako R, Lackner 
RP, Lanuti M, Lilenbaum R, Lin J, Loo Jr BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, 
Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, 
Hughes M. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. Journal of 
the National Comprehensive Cancer Network 2016; 14(7): 825-36. 
7. Buikhuisen WA, Burgers JA, Vincent AD, et al. Thalidomide versus active supportive care for 
maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an 
open-label, multicentre, randomised phase 3 study. Lancet Oncol 2013; 14(6): 543-51. 
8. Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural 
mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-
blind, randomised, placebo-controlled trial. Lancet Oncol 2015; 16(4): 447-56. 
9. Maio M, Scherpereel A, Calabro L, et al. Tremelimumab as second-line or third-line 
treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, 
randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol 2017; 18(9): 1261-73. 
10. Gregorc V, Gaafar RM, Favaretto A, et al. NGR-hTNF in combination with best investigator 
choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, 
placebo-controlled phase 3 trial. Lancet Oncol 2018; 19(6): 799-811. 
11. S A Burgers CdG, R Cornelissen, J G Aerts, B Biesma, R V Heemst, M Youssef-El Soud, H J M 
Groen, A J Staal-van den Brekel, G Bootsma, J H E M Schijen, P Baas, E Giovannetti, J F de Vries, F A 
Hogenboom, D C M de Wit, M C W Mahn- Schaefers, F Lalezari, V van de Noort, J Stigt. Switch 
maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A 
multicenter open label phase II trial (NVALT19).  October 2019: Annals of Oncology. 
12. Ou WB, Hubert C, Corson JM, et al. Targeted inhibition of multiple receptor tyrosine kinases 
in mesothelioma. Neoplasia 2011; 13(1): 12-22. 
13. Busacca S, Law EW, Powley IR, et al. Resistance to HSP90 inhibition involving loss of MCL1 
addiction. Oncogene 2016; 35(12): 1483-92. 
14. Fitzgerald DM, Hastings PJ, Rosenberg SM. Stress-Induced Mutagenesis: Implications in 
Cancer and Drug Resistance. Annu Rev Cancer Biol 2017; 1: 119-40. 
15. Chen G, Bradford WD, Seidel CW, Li R. Hsp90 stress potentiates rapid cellular adaptation 
through induction of aneuploidy. Nature 2012; 482(7384): 246-50. 
16. Lee JH, Park JH, Jung Y, et al. Histone deacetylase inhibitor enhances 5-fluorouracil 




17. Roh JL, Kim EH, Park HB, Park JY. The Hsp90 inhibitor 17-(allylamino)-17-
demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis 
in head and neck cancer. Cell Death Dis 2013; 4: e956. 
18. Proia DA, Bates RC. Ganetespib and HSP90: translating preclinical hypotheses into clinical 
promise. Cancer Res 2014; 74(5): 1294-300. 
19. Goldman JW, Raju RN, Gordon GA, et al. A first in human, safety, pharmacokinetics, and 
clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-
9090) in patients with solid malignancies. BMC Cancer 2013; 13: 152. 
20. Mbofung RM, McKenzie JA, Malu S, et al. HSP90 inhibition enhances cancer immunotherapy 
by upregulating interferon response genes. Nat Commun 2017; 8(451): 1-8. 
21. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant 
pleural mesothelioma. Ann Oncol 2004; 15(2): 257-60. 
22. Foster JM OA, Togneri FS, Vasques FR, Hau D, Taylor M, Tinkler-Hundal E, Southward K, 
Medlow P, McGreeghan-Crosby K, Halfpenny I, McMullan DJ, Quirke P, Keating KE, Griffiths M, Spink 
KG, Brew F. Cross-laboratory Validation of the OncoScan® FFPE Assay, a Multiplex Tool for Whole 
Genome Tumour Profiling. BMC Medical Genomics 2015; 8(5): 1-13. 
23. StataCorp. Stata Statistical Software: Release 15.: College Station, TX: StataCorp LLC; 2017. 
24. Fennell DA, Parmar A, Shamash J, et al. Statistical validation of the EORTC prognostic model 
for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 2005; 
23(1): 184-9. 
25. Fang Q, Inanc B, Schamus S, et al. HSP90 regulates DNA repair via the interaction between 
XRCC1 and DNA polymerase beta. Nat Commun 2014; 5: 5513. 
26. Stecklein SR, Kumaraswamy E, Behbod F, et al. BRCA1 and HSP90 cooperate in homologous 
and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. Proc Natl 
Acad Sci U S A 2012; 109(34): 13650-5. 
27. Abu Lila AS, Kato C, Fukushima M, Huang CL, Wada H, Ishida T. Downregulation of 
thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an 
orthotopic malignant mesothelioma xenograft mouse model. Int J Oncol 2016; 48(4): 1399-407. 
28. Righi L, Papotti MG, Ceppi P, et al. Thymidylate synthase but not excision repair cross-
complementation group 1 tumor expression predicts outcome in patients with malignant pleural 
mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 2010; 28(9): 1534-9. 
29. Zucali PA, Giovannetti E, Destro A, et al. Thymidylate synthase and excision repair cross-
complementing group-1 as predictors of responsiveness in mesothelioma patients treated with 
pemetrexed/carboplatin. Clin Cancer Res 2011; 17(8): 2581-90. 
30. Ivanov SV, Miller J, Lucito R, et al. Genomic events associated with progression of pleural 
malignant mesothelioma. Int J Cancer 2009; 124(3): 589-99. 
31. Patrick M. Forde ZS, Valsamo Anagnostou, Hedy L. Kindler, William T. Purcell, Bernardo H. L. 
Goulart, Arkadiusz Z. Dudek, Hossein Borghaei, Julie R. Brahmer, Suresh S. Ramalingam. PrE0505: 
Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed 
for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC 
study. J Clin Oncol 2020; 38(suppl; abstr 9003). 
32. Squibb BM. Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 
Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously 
Untreated Malignant Pleural Mesothelioma.  Opdivo plus Yervoy prolonged survival compared to 
chemotherapy at interim analysis in CheckMate -743; 2020. 
33. Mbofung RM, McKenzie JA, Malu S, et al. HSP90 inhibition enhances cancer immunotherapy 






Table 1. Patient characteristics at baseline. 
Characteristic No. (N = 27) % 
Age (years)     
  Median (range) 66 (37-76) 
Sex 
Female 2 7 
Male 25 93 
Histology     
  Epithelioid 21 78 
  Non-epithelioid 6 22 
ECOG Performance 
Status 
0 6 22 
1 21 78 
EORTC Prognostic Score   
 Good 2 7 
 Poor 25 93 
Platinum Treatment     
  Cisplatin 16 59 
  Carboplatin 11 41 
Ganetespib Dose (mg/m2) 
100 5 (1 Carboplatin) 
150 4 (1 Carboplatin) 
  200 18 (9 Carboplatin) 
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EORTC, European 









Table 2. Number of patients with maximum grade 3 or 4 adverse events, per platinum-
therapy cohort and ganetespib dose level (number of patients experiencing grade 4 shown in 
parentheses). 
Ganetespib Dose (mg/m2) 
Cisplatin  Carboplatin 
100 150 200  100 150 200 
(n = 4) (n = 3) (n = 9)  (n = 1) (n = 1) (n = 9) 
    
Haematological/ 
Biochemical AEs    
 
   
Anemia 1 . 3  . . 2 
Hyperglycemia . . 1  . . . 
Hyperkalemia . . .  . . 1 
Hypokalemia . . .  . . 1 
Hyponatremia . . .  . . 1 
Neutrophil count decreased . . 2(1)  1(1) . 1 
Platelet count decreased . . .  . . 3(1) 
 
Symptomatic AEs    
 
   
Acute kidney injury . . 1  . . . 
Anxiety . . 1  . . . 
Apnea . . 1  . . . 
Ascites . . .  . . 1 
Chest wall pain . . 1  . . . 
Diarrhea . . 1  . . 1 
Dyspnea 1 . .  . . . 
Hearing impaired . 1(1) .  . . . 
Infections (chest) . 1 .  . . . 
Lung infection . . .  . . 1 
Nausea . . 3  . . 1 
Pleural effusion . . .  . . 1 
Sepsis . . 1(1)  . . . 
Sleep apnea . . 1  . . . 
Syncope . . .  1 . . 
Upper respiratory infection 1 . .  1 . 1 
Vasculitis . . 1  . . . 
Vomiting . . 2  . . . 
Wound infection . . .  . . 2 
               






Table 3. Genomic variables and associations with best reduction in total tumor burden (TTB) 
and time to progression. TTB is the unidimensional measure corresponding to the sum of six 
pleural measurements determined by CT scan as per modified RECIST. 
Best percentage reduction in TTB (mm) from baseline 
(n = 7) 





Total SCNA 0.0714 0.879 
Total LOH -0.703 0.0782 
Total Homozygous Deletions -0.0541 0.908 
 
Time to Progression from treatment start (n = 11) 







Total SCNA 1.01 0.99 - 1.02 0.295 
Total LOH 1.12 1.02 - 1.24 0.018 
Total Homozygous Deletions 1.24 0.89 - 1.73 0.201 
Abbreviations: TTB, Total tumor burden; SCNA, Somatic Copy Number Alterations; LOH, 















FIGURES LEGENDS AND CAPTIONS 
 
 
Figure 1. Waterfall plot of best response by ganetespib dose in response-evaluable patients. 
Total Tumor Burden (TTB) is the unidimensional measure corresponding to the sum of six 
pleural measurements determined by CT as per modified RECIST. 
 

